Treatment of mesenteric desmoid tumours with the anti-oestrogenic agent toremifene: Case histories and an overview of the literature

European Journal of Gastroenterology and Hepatology

Volumn 11, Issue 10, 1999, Pages 1179-1183

  Bus, Paul J ^a   Verspaget, Hein W ^b   Van Krieken, Johannes H J M ^b   De Roos, Albert ^b   Keizer, H Jan ^b   Bemelman, Willem A ^b   Vasen, Hans F A ^b   Lamers, Cornelis B H W ^b   Griffioen, Gerrit ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Aggressive fibromatosis; Anti oestrogen; Desmoid tumours; Toremifene

Indexed keywords

ANTIESTROGEN; NONSTEROID ANTIINFLAMMATORY AGENT; SULINDAC; TOREMIFENE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DESMOID TUMOR; FAMILIAL POLYPOSIS; FEMALE; HUMAN; MALE; MEDICAL LITERATURE; MESENTERY TUMOR; PRIORITY JOURNAL; TUMOR VOLUME;

EID: 0033361121     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-199910000-00018     Document Type: Article

References (67)

1. 1 Pack GT, Ehlich HE. Neoplasms of the anterior abdominal wall with special consideration of desmoid tumours: experience with 391 cases and a collective review of the literature. International Abstract of Surgery 1944; 79:177-198.
2. 2 Dahn I, Jonsson N, Lundh G. Desmoid tumours. A series of 33 cases. Acta Chir Scand 1963; 126:305-314.
3. 3 Reitamo JJ, Häyry P, Nykyri E, Saxen E. The desmoid tumor. I. Incidence, sex-, age- and anatomical distribution in the Finnish population. Am J Clin Pathol 1982; 77:665-673.
4. 4 Reitamo JJ, Scheinin TM, Häyry P. The desmoid syndrome. New aspects in the cause, pathogenesis and treatment of the desmoid tumor. Am J Surg 1986; 151:230-237.
5. 5 Jones EL, Cornell WP. Gardner's syndrome: review of the literature and report of a family. Arch Surg 1966; 92:287-300.
6. 6 Jones IT, Fazio VW, Weakley FL, McGannon E. Desmoid tumors in familial polyposis coli. Ann Surg 1986; 204:94-97.
7. 7 Bussey HJR. Extracolonic lesions associated with polyposis coli. Proc Roy Soc Med 1972; 65:294-296.
8. 8 Naylor EW, Gardner EJ, Richards RC. Desmoid tumors and mesenteric fibromatosis in Gardner's syndrome: report of kindred 109. Arch Surg 1979; 114:1181-1185.
9. 9 Gurbuz AK, Giardiello FM, Petersen GM, Krush AJ, Offerhaus GJA, Booker SV, et al. Desmoid tumours in familial adenomatous polyposis. Gut 1994; 35:377-381.
10. 10 Bülow S. Incidence of associated diseases in familial polyposis coli. Semin Surg Oncol 1987; 3:84-87.
11. 11 Richards RC, Rogers SW, Gardner EJ. Spontaneous mesenteric fibromatosis in Gardner's syndrome. Cancer 1981; 47:597-601.
12. 12 Lynch HT, Fritzgibbons R, Chong S, Cavalieri J, Lynch J, Wallace F, Patel S. Use of doxorubicin and dacarbazine for the management of unresectable intra-abdomlnal desmoid tumors in Gardner's syndrome. Dis Colon Rectum 1994; 37:260-267.
13. 13 Clark SK, Phillips RKS. Desmoids in familial adenomatous polyposis. Br J Surg 1996; 83:1494-1504.
14. 14 Jones IT, Jagelman DG, Fazio VW, Lavery IC, Weakley FL, McGannon E. Desmoid tumors in familial polyposis coli. Ann Surg 1986; 204:94-97.
15. 15 Rodriguez-Bigas MA, Mahoney MC, Karakousis CP, Petrelli NJ. Desmoid tumors in patients with familial adenomatous polyposis. Cancer 1994; 74:1270-1274.
16. 16 Häyry P, Reitamo JJ, Tötterman S, Hopfner-Hallikainen D, Sivula A. The desmoid tumor II. Analysis of factors possibly contributing to the etiology and growth behavior. Am J Clin Pathol 1982; 77:674-680.
17. 17 Penna C, Tiret E, Parc R, Sfairi A, Kartheuser A, Hannoun L, Nordlinger B. Operation and abdominal desmoid tumors in familial adenomatous polyposis. Surg Gynecol Obstet 1993; 177:263-268.
18. 18 Caspari R, Olschwang S, Friedl W. Familial adenomatous polyposis: desmoid tumours and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444. Hum Mol Genet 1995; 4:337-340.
19. 19 Arvanitis ML, Jagelman DG, Fazio VW, Lavery IC, McGannon E. Mortality in patients with familial adenomatous polyposis. Dis Colon Rectum 1990; 33:639-642.
20. 20 Posner MC, Shiu MH, Newsome JL, Hajdu SI, Gaynor JJ, Brennan MF. The desmoid tumor. Arch Surg 1989; 124:191-196.
21. 21 Waddell WR, Gerner RE, Reich MP. Non-steroid antiinflammatory drugs and tamoxifen for desmoid tumors and carcinoma of the stomach. J Surg Oncol 1983; 22:197-211.
22. 22 Moertel CG, Hill JR, Adson MA. Management of multiple polyposis of the large bowel. Cancer 1971; 28:160-164.
23. 23 Khorsand J, Karakosis CP. Desmoid tumors and their management. Am J Surg 1985; 149:215-218.
24. 24 Jagelman DG. Extracolonic manifestations of familial polyposis coli. Semin Surg Oncol 1987; 3:88-91.
25. 25 Karakosis CP, Berjian RA, Lopez R, Rao U. Mesenteric fibromatosis in Gardner's syndrome. Arch Surg 1978; 113:998-1000.
26. 26 Richards RC, Rogers SW, Gardner EJ. Spontaneous mesenteric fibromatosis in Gardner's syndrome. Cancer 1981; 47:597-601.
27. 27 Jarvinen HJ. Desmoid disease as a part of familial adenomatous polyposis coli. Acta Chir Scand 1987; 153:379-383.
28. 28 Dong-Heup K, Kim DH, Goldsmith HS, Quan SH, Huvos AG. Intra-abdominal desmoid tumor. Cancer 1971; 27:1041-1051.
29. 29 Johnson JG, Giulbert E, Zimmermann B, Watne AL. Gardner's syndrome, colon cancer, and sarcoma. J Surg Oncol 1972; 4:354-362.
30. 30 Assad WA, Nori D, Hilaris BS, Shiu MH, Hajdu SI. Role of brachytherapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys 1986; 12:901-906.
31. 31 Zelefsky MJ, Harrison LB, Shiu MH, Armstrong JG, Hajdu SI, Brennan MF. Combined surgical resection and iridium 192 implantation for locally advanced and recurrent desmoid tumors. Cancer 1991; 67:380-384.
32. 32 Kiel KD, Suit HD. Radiation therapy in the treatment of aggressive fibromatoses (desmoid tumors). Cancer 1984; 54:2051-2055.
33. 33 Weiss AJ, Lackman RD. Therapy of desmoid tumors, fibromatosis, and related neoplasms. Int J Oncol 1995; 7:773-776.
34. 34 Tsukada K, Church JM, Jagelman DG, Fazio VW, Lavery IC. Systemic cytotoxic chemotherapy and radiation therapy for desmoid in familial adenomatous polyposis. Dis Colon Rectum 1991; 34:1090-1092.
35. 35 Kitamura A, Kanagawa T, Yamada S, Kawai T. Effective chemotherapy for abdominal desmoid in a patient with Gardner's syndrome: report of a case. Dis Colon Rectum 1991; 34:822-826.
36. 36 Tsukada K, Church JM, Jagelman DG, Fazio VW, McGannon E, George CR, et al. Noncytotoxic drug therapy for intra-abdominal desmoid tumor in patients with familial adenomatous polyposis. Dis Colon Rectum 1992; 35:29-33.
37. 37 Waddell WR, Kirsch WM. Testolactone, sulindac, warfarin, and vitamin K1 for unresectable desmoid tumors. Am J Surg 1991; 161:416-421.
38. 38 Belliveau P, Graham AM. Mesenteric desmoid tumor in Gardner's syndrome treated by sulindac. Dis Colon Rectum 1984; 27:53-54.
39. 39 Pasricha PJ, Bedi A, O'Connor K, Rashid A, Akhtar AJ, Zahurak ML, et al. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 1995; 109:994-998.
40. 40 Spagnesi MT, Tonelli F, Dolara P, Caderni G, Valanzano R, Anastasi A, Bianchini F. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Gastroenterology 1994; 106:362-366.
41. 41 Piazza GA, Kulchak Rahm AL, Krutzch M, Sperl G, Shipp Paranka N, Gross PH, et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 1995; 55:3110-3116.
42. 42 De Mello MCF, Bayer BM, Beaven MA. Evidence that prostaglandins do not have a role in the cytostatic action of anti-inflammatory drugs. Biochem Pharmacol 1980; 29:311-318.
43. 43 Rock MG, Pritchard DJ, Reiman HM, Soule EH, Brewster RC. Extraabdominal desmoid tumors. J Bone Joint Surg 1984; 66:1369-1374.
44. 44 Eagel BA, Zentler-Munro P, Smith IE. Mesenteric desmoid tumours in Gardner's syndrome - review of medical treatments. Postgrad Med J 1989; 65:497-501.
45. 45 Nadel EM. Histopathology of estrogen-induced tumours in guinea pigs. J Natl Cancer Inst 1950; 10:1043-1065.
46. 46 Kinzbrunner B, Ritter S, Domingo J, Rosenthal CJ. Remission of rapidly growing desmoid tumors after tamoxifen therapy. Cancer 1983; 52:2201-2204.
47. 47 Procter H, Singh L, Baum M, Brinkley D. Response of multicentric desmoid tumours to tamoxifen. Br J Surg 1987; 74:401.
48. 48 Bauernhofer T, Stöger H, Schmid M, Smola M, Gürtl B, Höfler G, et al. Sequential treatment of recurrent mesenteric desmoid tumor. Cancer 1996; 77:1061-1065.
49. 49 Wilcken N, Tattersall MHN. Endocrine therapy for desmoid tumors. Cancer 1991; 68:1384-1388.
50. 50 Tonelli F, Valanzano R, Brandi ML. Pharmacologic treatment of desmoid tumors in familial adenomatous polyposis: results of an in vitro study. Surgery 1994; 115:473-479.
51. 51 Wilson AJ, Baum M, Singh L, Kangas L. Antioestrogen therapy of pure mesenchymal tumour. Lancet 1987; ii:508.
52. 52 Häyry P, Reitamo JJ, Vihko R, Jänne O, Scheinin TM, Tötterman S, et al. The desmoid tumor III. A biochemical and genetic analysis. Am J Clin Pathol 1982; 77:681-685.
53. 53 Sutherland RL, Murphy LC, Foo MS, Green MD, Whybourne AM, Krozowski ZS. High affinity antiestrogen binding site distinct from the estrogen receptor. Nature 1980; 288:273-275.
54. 54 Watts CKW, Murphy LC, Sutherland RL. Microsomal binding sites for non-steroidal antioestogens in MCF-7 human mammary carcinoma cells. Demonstration of high affinity and narrow specificity for basic ether derivatives of triphenylethylene. J Biol Chem 1984; 259:4223.
55. 55 Lim CL, Walker MJ, Mehta RR, Das Gupta TK. Estrogen and antiestrogen binding sites in desmoid tumors. Eur J Cancer Clin Oncol 1986; 22:583-587.
56. 56 Colletta AA, Wakefield LM, Howell FV, van Roozendaal KEP, Danielpour D, Ebbs SR, et al. Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br J Cancer 1990; 62:405-409.
57. 57 Benson JR, Baum M. Breast cancer, desmoid tumours, and familial adenomatous polyposis - a unifying hypothesis. Lancet 1993; 342:848-850.
58. 58 Gagliardi A, Collins DC. Inhibition of angiogenesis by antiestrogens. Cancer Res 1993; 53:533-535.
59. 59 Lindner DJ, Borden EC. Effects of tamoxifen and interferon-beta or the combination on tumor-induced angiogenesis. Int J Cancer 1997; 71:456-461.
60. 60 Hard GC, latropoulos MJ, Jordan K, Radi L, Kaltenberg OP, Imondi AR, Williams GM. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res 1993; 53:4534-4541.
61. 61 Kangas L. Review of the pharmacological properties of toremifene. J Steroid Biochem 1990; 36:191-195.
62. 62 Hamm JT. Phase I and II studies of toremifene. Oncology 1997; 11(suppl 4):19-22.
63. 63 Gams R. Phase III trials of toremifene vs tamoxifen. Oncology 1997; 11 (suppl 4):23-28.
64. 64 Williams GM, Jeffrey AM. Safety assessment of tamoxifen and toremifene. Oncology 1997; 11(suppl 4):41-47.
65. 65 Gershanovich M, Hayes DF, Ellmen J, Vuorinen J. High-dose toremifene vs tamoxifen in postmenopausal advanced breast cancer. Oncology 1997; 11 (suppl 4):29-36.
66. 66 Ebbs SR, Roberts J, Baum M. Response to toremifene (Fc-1157a) therapy in tamoxifen failed patients with breast cancer. Preliminary communication. J Steroid Biochem 1990; 36:239.
67. 67 Brooks MD, Ebbs SR, Colletta AA, Baum M. Desmoid tumours treated with triphenylethylenes. Eur J Cancer 1992; 28:1014-1018.